SIGA Technologies Inc. - Form 8-K Summary
Business Context and Reporting Period
Date: June 9, 2004
Company: SIGA Technologies, Inc. (Delaware Corporation)
Event: Signing of an Asset Purchase Agreement to acquire antiviral programs from ViroPharma Incorporated (VPHM).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain periodic financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Transaction Details
- Acquisition Target: Certain antiviral programs targeting potential agents of biological warfare, including smallpox and hemorrhagic fever viruses (e.g., Ebola).
- Assets Acquired: Lead compounds, assays, and scientific know-how.
- Consideration: $1 million in cash and 1 million shares of SIGA common stock.
- Current Status: The acquired programs are currently supported by grants from the National Institutes of Health (NIH).
- Closing Conditions: Subject to customary conditions, including approval for the transfer of NIH grants.
Outlook, Risks, and Management Commentary
Management has announced the strategic move to expand its portfolio in antiviral drug development. The primary contingency identified is the regulatory requirement to obtain approval for the transfer of existing NIH grants to SIGA. The transaction is not yet closed.
Key Facts for Investor Verification
- Confirmation of the closing date and successful transfer of NIH grants.
- Valuation of the 1 million shares of SIGA common stock issued as part of the consideration.
- Impact of the $1 million cash outlay on SIGA's current liquidity position.
- Details regarding the specific lead compounds and development stage of the acquired programs.